Trial Profile
Phase I trial of the safety, tolerability, pharmacokinetics and initial efficacy of CM082 in the treatment of wet age-related macular degeneration (wAMD)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Dec 2017
Price :
$35
*
At a glance
- Drugs Vorolanib (Primary)
- Indications Wet age-related macular degeneration
- Focus Pharmacokinetics; Therapeutic Use
- 26 Dec 2017 New trial record